EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Polycomb scaffolding subunit EED supports the SCLC neuroendocrine identity and EGFR-mutant LUAD-to-SCLC transformation

Yixiang Li, Yasmin N Laimon, Hyeonseo Cho, Marina Vivero, Gabriel Roberti De Oliveira, Maxwell D Seager, Andrew Delcea, Varunika Savla, Yuting Chen, Yavuz T Durmaz, Xintao Qiu, Shweta Kukreja und 14 weitere

Journal of Clinical Investigation · 2026

DOI: 10.1172/jci199454 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Yixiang Li und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, and. Hauptthemen laut MEDLINE: Lung Neoplasms, Small Cell Lung Carcinoma, Cell Transformation, Neoplastic, Mutation. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, American Cancer Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer histological subtypes include lung adenocarcinoma (LUAD) and small-cell lung cancer (SCLC). Although usually distinct, rare combined LUAD/SCLC tumors occur, and LUAD can transform into SCLC as a mechanism of resistance to targeted therapies, particularly in EGFR -mutant LUAD tumors with RB1/TP53 inactivation. Although PRC2 complex expression increases during this transformation, its functional role remains unclear. Using CRISPR-based autochthonous immunocompetent GEMMs, we found that inactivation of EED, the core PRC2 scaffolding subunit, impaired SCLC tumorigenesis and promoted LUAD histological identity, likely through a NEUROD1-positive intermediate state. Mechanistically, EED loss derepressed bivalent genes comarked by H3K27me3 and H3K4me3, including LUAD oncogenic RAS, PI3K, and MAPK pathway genes and NEUROD1. These same LUAD oncogenic signaling genes were bivalently repressed in human SCLC patient-derived xenografts, suggesting a conserved PRC2-dependent mechanism that represses LUAD oncogenic signaling and thereby supports the SCLC neuroendocrine identity. In a complementary EGFR -mutant LUAD GEMM with Rb1 and Trp53 inactivation, EED inactivation at tumor initiation prevented the emergence of SCLC histology after EGFR oncogene withdrawal and redirected recurrent tumors toward mucinous LUAD states with reduced spontaneous metastasis. These findings identify PRC2/EED as a regulator of SCLC neuroendocrine identity and nominate pharmacologic EED inhibition for future investigation in therapy-associated LUAD-to-SCLC transformation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsSmall Cell Lung CarcinomaCell Transformation, NeoplasticMutationPolycomb Repressive Complex 2Adenocarcinoma of LungNeoplasm ProteinsAnimalsHumansErbB ReceptorsMiceBasic Helix-Loop-Helix Proteins

Stichwörter der Autor:innen

EpigeneticsGeneticsLung cancerMouse modelsOncology

Substanzen

ErbB ReceptorsPolycomb Repressive Complex 2Neoplasm ProteinsEGFR protein, humanEGFR protein, mouseBasic Helix-Loop-Helix ProteinsNEUROD1 protein, human

Autor:innen und Institutionen

  • Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, and.
  • Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai, China.
  • Center for Functional Cancer Epigenetics and.
  • Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA.

Förderung

  • NCI NIH HHS
  • National Cancer Institute
  • American Cancer Society
  • The Neil S. Hirsch Foundation
  • The Kaplan Family Fund

Zitieren

APA

Li, Y., Laimon, Y. N., Cho, H., Vivero, M., De Oliveira, G. R., Seager, M. D., Delcea, A., Savla, V., Chen, Y., Durmaz, Y. T., Qiu, X., Kukreja, S., Li, R., El Zarif, T., Lu, W., Van Orden, M., Berchuck, J. E., Bronson, R. T., Li, S., …, & Oser, M. G. (2026). Polycomb scaffolding subunit EED supports the SCLC neuroendocrine identity and EGFR-mutant LUAD-to-SCLC transformation. Journal of Clinical Investigation. https://doi.org/10.1172/jci199454

Vancouver

Li Y, Laimon YN, Cho H, Vivero M, De Oliveira GR, Seager MD, et al. Polycomb scaffolding subunit EED supports the SCLC neuroendocrine identity and EGFR-mutant LUAD-to-SCLC transformation. Journal of Clinical Investigation. 2026. doi:10.1172/jci199454

BibTeX
@article{Li2026,
  author = {Li, Yixiang and Laimon, Yasmin N and Cho, Hyeonseo and Vivero, Marina and De Oliveira, Gabriel Roberti and Seager, Maxwell D and Delcea, Andrew and Savla, Varunika and Chen, Yuting and Durmaz, Yavuz T and Qiu, Xintao and Kukreja, Shweta and Li, Rong and El Zarif, Talal and Lu, Wesley and Van Orden, McKayla and Berchuck, Jacob E and Bronson, Roderick T and Li, Shuqiang and Ji, Hongbin and Barbie, David A and Politi, Katerina and Freedman, Matthew L and Long, Henry W and Signoretti, Sabina and Oser, Matthew G},
  title = {Polycomb scaffolding subunit EED supports the SCLC neuroendocrine identity and EGFR-mutant LUAD-to-SCLC transformation},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  doi = {10.1172/jci199454}
}
Kostenlos starten →